Brokerages Set PolyPid Ltd. (NASDAQ:PYPD) Target Price at $12.40

by · The Cerbat Gem

Shares of PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) have received an average rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $12.40.

A number of equities research analysts have recently issued reports on PYPD shares. Citigroup reissued a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Roth Capital dropped their price objective on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings restated a “sell (e+)” rating on shares of PolyPid in a research report on Wednesday, October 8th. Finally, Craig Hallum reiterated a “buy” rating and issued a $13.00 price target (down from $15.00) on shares of PolyPid in a research report on Thursday, August 14th.

View Our Latest Stock Report on PYPD

PolyPid Trading Down 0.7%

Shares of NASDAQ PYPD opened at $3.98 on Tuesday. The firm has a market cap of $63.28 million, a P/E ratio of -1.34 and a beta of 1.49. The business’s 50 day moving average is $3.64 and its 200-day moving average is $3.49. PolyPid has a 1-year low of $2.30 and a 1-year high of $4.07.

PolyPid (NASDAQ:PYPD – Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.17. Analysts forecast that PolyPid will post -1.79 EPS for the current year.

Hedge Funds Weigh In On PolyPid

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its holdings in shares of PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after purchasing an additional 3,500 shares in the last quarter. Lumbard & Kellner LLC bought a new stake in PolyPid during the second quarter worth about $135,000. Finally, AIGH Capital Management LLC grew its stake in PolyPid by 27.0% during the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after buying an additional 253,727 shares in the last quarter. 26.47% of the stock is owned by institutional investors and hedge funds.

About PolyPid

(Get Free Report)

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.

Read More